Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

The FDA has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular lymphoma.

The research points to effective new treatment options for KSHV-associated cancers, including Kaposi's sarcoma, primary effusion lymphoma, and HHV8-associated multicentric Castleman disease.

Primary CNS Burkitt Lymphoma Primary CNS Burkitt lymphoma (PCNSBL) is very rare, affecting individuals from 6 months to 75 years old. Only 38 cases of PCNSBL have been documented, according to a study ...

“Historically, this presentation has been associated with primary effusion lymphoma (PEL), a human herpesvirus 8 (HHV8)–positive B-cell lymphoma with a predilection for patients that are ...

Common subtypes of NHLs associated with AIDS include Burkitt’s lymphoma, diffuse large cell lymphoma, primary central nervous system lymphoma, plasmablastic lymphoma, and primary effusion ...

Primary effusion lymphoma (PEL) is an aggressive post-germinal center B-cell lymphoma. It is directly linked to the γ-herpesvirus, Kaposi’s sarcoma-associated herpesvirus (KSHV; HHV8) ( 4 ). PEL is ...

Primary effusion lymphoma (PEL) is an incurable non-Hodgkin's lymphoma and novel biology-based treatments are urgently needed in clinical settings. Shikonin (SHK), a napthoquinone derivative, has been ...

Primary effusion lymphoma (PEL) is an aggressive B-cell lymphoma confined to body cavities and universally associated with human herpesvirus type 8 infection. The prognosis of this entity remains poor ...

A 59-year-old Caucasian man infected with HIV, in remission from human herpes virus-8-positive extracavitary primary effusion lymphoma (EC-PEL), presented to a sexual health clinic with fever and ...

One of these NHL subtypes is primary effusion lymphoma (PEL), which is associated with Kaposi’s sarcoma-associated herpesvirus (KSHV). Patients with PEL have a median survival time of 6 mo after ...